CHEK2 and breast cancer: There is similarly little data on BC risk and phenotype in CHEK2 homozygotes or compound heterozygotes, although available data suggests that these patients may have higher BC risk, present at younger age, and more often have a second BC diagnosis compared to heterozygotes [45–47].